Serum endocan levels in multiple sclerosis relapse and remission

Basit Öğe Kaydı
dc.contributor.authorAkil, E.
dc.contributor.authorAlp, R.
dc.contributor.authorAluclu, M. U.
dc.contributor.authorAcar, A.
dc.contributor.authorKaplan, I
dc.date.accessioned2024-04-24T17:20:22Z
dc.date.available2024-04-24T17:20:22Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractOBJECTIVE: Endocan has been defined as an important marker of inflammatory diseases, vascular and endothelial injury, tumour progression, cell adhesion and angiogenesis. In our study, we compared the serum endocan, C-reactive protein (CRP) and neutrophil- lymphocyte ratio (NLR) levels of relapsing-remitting multiple sclerosis (RRMS) patients in remission and in relapse. PATIENTS AND METHODS: This study included 53 RRMS remission patients, 30 RRMS relapse/post-relapse patients and 44 healthy volunteers. Blood samples were collected once from RRMS patients in remission and from the control group. and twice from RRMS relapse patients: once when relapsing and another 1 month after relapse. The endocan, CRP and NLR levels of the RRMS patients measured while in relapse. 1 month after relapse and while in remission were compared to those of the control group. The studied parameters were compared with the disease duration, relapse frequency, Expanded Disability Status Scale (EDSS) score, applied treatment and lesion burden assessed using magnetic resonance imaging (MRI). RESULTS: The endocan, CRP and NLR levels were significantly higher in the RRMS group than in the control group (p < 0.05). The serum endocan levels were found to be significantly higher in the RRMS relapse group than in the post-relapse and control groups (p < 0.05). There were no significant correlations between the disease duration. EDSS score, relapse frequency and lesion burden on MRI and the endocan, CRP and NLR values (p > 0.05). According to the correlation analysis, there was a statistically strong positive relationship between the MRI lesion localisation and the EDSS score, disease duration and relapse frequency (p < 0.001). CONCLUSIONS: Endocan increase is a marker of the endothelial injury that develops secondary to the inflammatory process in MS patients. It can thus be considered a moderately good indicator of relapse.en_US
dc.identifier.doi10.26355/eurrev_202106_26051
dc.identifier.endpage4098en_US
dc.identifier.issn1128-3602
dc.identifier.issue11en_US
dc.identifier.pmid34156688
dc.identifier.scopus2-s2.0-85108558494
dc.identifier.scopusqualityQ2
dc.identifier.startpage4091en_US
dc.identifier.urihttps://doi.org/10.26355/eurrev_202106_26051
dc.identifier.urihttps://hdl.handle.net/11468/18986
dc.identifier.volume25en_US
dc.identifier.wosWOS:000662246300021
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRelapsing-Remitting Multiple Sclerosisen_US
dc.subjectEndocanen_US
dc.subjectC-Reactive Proteinen_US
dc.subjectNeutrophil-Lymphocyte Ratioen_US
dc.titleSerum endocan levels in multiple sclerosis relapse and remissionen_US
dc.titleSerum endocan levels in multiple sclerosis relapse and remission
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu